In vivo imaging of Bcr-Abl overexpressing tumors with a radiolabeled imatinib analog as an imaging surrogate for imatinib

AP Glekas, NK Pillarsetty, B Punzalan… - Journal of Nuclear …, 2011 - Soc Nuclear Med
Imatinib mesylate is a tyrosine kinase inhibitor that was approved by the US Food and Drug
Administration in 2001 for treatment of many different stages of chronic myeloid leukemia …

Imatinib analogs as potential agents for PET imaging of Bcr-Abl and c-KIT expression at a kinase level

Z Peng, DS Maxwell, D Sun, BAB Prasad, A Pal… - Bioorganic & medicinal …, 2014 - Elsevier
We synthesized two series of imatinib mesylate (STI-571) analogs to develop a Bcr-Abl and
c-KIT receptor-specific labeling agent for positron emission tomography (PET) imaging to …

Synthesis and positron emission tomography studies of carbon-11-labeled imatinib (Gleevec)

KE Kil, YS Ding, KS Lin, D Alexoff, SW Kim… - Nuclear medicine and …, 2007 - Elsevier
INTRODUCTION: Imatinib mesylate (Gleevec) is a well known drug for treating chronic
myeloid leukemia and gastrointestinal stromal tumors. Its active ingredient, imatinib ([4-[(4 …

124I-Iodopyridopyrimidinone for PET of Abl Kinase–Expressing Tumors In Vivo

M Doubrovin, T Kochetkova, E Santos… - Journal of Nuclear …, 2010 - Soc Nuclear Med
Because of the recent development of an iodopyridopyrimidinone Abl protein kinase
inhibitor (PKI), 124I-SKI-212230 (124I-SKI230), we investigated the feasibility of a PET …

Synthesis of imatinib, a tyrosine kinase inhibitor, labeled with carbon‐14

J Kang, JY Lee, JH Park… - Journal of Labelled …, 2020 - Wiley Online Library
Imatinib (Gleevec) is a multiple tyrosine kinase inhibitor that decreases the activity of the
fusion oncogene called BCR‐ABL (breakpoint cluster region protein‐Abelson murine …

Molecular imaging of Bcr-Abl phosphokinase in a xenograft model

JY Wu, DJ Yang, LS Angelo, S Kohanim… - Molecular cancer …, 2009 - AACR
The purpose of this study was to determine whether the Bcr-Abl tyrosine kinase can be
assessed by γ-imaging using an 111In-labeled anti-phosphotyrosine (APT) antibody, and if …

First-in-Humans Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted PET

S Krebs, DR Veach, LM Carter, M Grkovski… - Journal of Nuclear …, 2020 - Soc Nuclear Med
We developed a first-of-kind dasatinib-derivative imaging agent, 18F-SKI-249380 (18F-SKI),
and validated its use for noninvasive in vivo tyrosine kinase-targeted tumor detection in …

[PDF][PDF] Clinical pharmacokinetics of imatinib mesylate

D Levêque, F Maloisel - in vivo, 2005 - iv.iiarjournals.org
This review presents the clinical pharmacokinetics of imatinib mesylate. Aspects regarding
absorption, tissue distribution, elimination and kinetic interactions are also discussed …

Alpha-Particle Therapy for Acute Myeloid Leukemia☆☆☆

J Jurcic - Journal of Medical Imaging and Radiation Sciences, 2019 - jmirs.org
Objectives: Insulin-like growth factor-1 receptor (IGF-1R) is an oncogenic protein that is over-
expressed in multiple solid tumors. IGF-1R targeted therapeutics have not demonstrated …

Molecular imaging of post-Src inhibition tumor signatures for guiding dasatinib combination therapy

L Gao, H Liu, X Sun, D Gao, C Zhang… - Journal of Nuclear …, 2016 - Soc Nuclear Med
Noninvasive, real-time, quantitative measurement of key biomarkers associated with cancer
therapeutic interventions could provide a better understanding of cancer biology. We …